Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1242

1.

Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.

Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ.

Gastroenterology. 2009 Dec;137(6):2146-57. doi: 10.1053/j.gastro.2009.09.004. Epub 2009 Sep 17.

PMID:
19766644
2.

The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes.

Jessen L, D'Alessio D.

Gastroenterology. 2009 Dec;137(6):1891-4. doi: 10.1053/j.gastro.2009.10.013. Epub 2009 Oct 29. No abstract available.

PMID:
19879210
3.

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.

Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ.

Diabetes. 2004 May;53(5):1326-35.

4.

GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.

Hansotia T, Drucker DJ.

Regul Pept. 2005 Jun 15;128(2):125-34. Review.

PMID:
15780432
5.

Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.

Kim SJ, Nian C, Doudet DJ, McIntosh CH.

Diabetes. 2008 May;57(5):1331-9. doi: 10.2337/db07-1639. Epub 2008 Feb 25.

6.

Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.

Waget A, Cabou C, Masseboeuf M, Cattan P, Armanet M, Karaca M, Castel J, Garret C, Payros G, Maida A, Sulpice T, Holst JJ, Drucker DJ, Magnan C, Burcelin R.

Endocrinology. 2011 Aug;152(8):3018-29. doi: 10.1210/en.2011-0286. Epub 2011 Jun 14.

PMID:
21673098
7.

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.

Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ.

J Biol Chem. 2003 Jan 3;278(1):471-8. Epub 2002 Oct 29.

8.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
9.
10.

Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.

Pamir N, Lynn FC, Buchan AM, Ehses J, Hinke SA, Pospisilik JA, Miyawaki K, Yamada Y, Seino Y, McIntosh CH, Pederson RA.

Am J Physiol Endocrinol Metab. 2003 May;284(5):E931-9. Epub 2003 Jan 21.

12.

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.

Maida A, Lamont BJ, Cao X, Drucker DJ.

Diabetologia. 2011 Feb;54(2):339-49. doi: 10.1007/s00125-010-1937-z. Epub 2010 Oct 23.

PMID:
20972533
13.

Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice.

Lamont BJ, Drucker DJ.

Diabetes. 2008 Jan;57(1):190-8. Epub 2007 Oct 10.

14.

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA.

Diabetes. 2003 Mar;52(3):741-50.

15.

Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.

Freeman JS.

Cleve Clin J Med. 2009 Dec;76 Suppl 5:S12-9. doi: 10.3949/ccjm.76.s5.03. Review.

16.

A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.

Bhat VK, Kerr BD, Vasu S, Flatt PR, Gault VA.

Diabetologia. 2013 Jun;56(6):1417-24. doi: 10.1007/s00125-013-2892-2. Epub 2013 Mar 17.

PMID:
23503814
17.

Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes.

Shirakawa J, Amo K, Ohminami H, Orime K, Togashi Y, Ito Y, Tajima K, Koganei M, Sasaki H, Takeda E, Terauchi Y.

J Biol Chem. 2011 Jul 22;286(29):25467-76. doi: 10.1074/jbc.M110.217216. Epub 2011 May 25.

18.

Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.

Bahrami J, Longuet C, Baggio LL, Li K, Drucker DJ.

Gastroenterology. 2010 Sep;139(3):857-68. doi: 10.1053/j.gastro.2010.05.006. Epub 2010 Jun 11.

PMID:
20546737
19.

Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.

Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.

Regul Pept. 2012 Nov 10;179(1-3):91-100. doi: 10.1016/j.regpep.2012.08.016. Epub 2012 Sep 15.

PMID:
22989472
20.

Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors.

Preitner F, Ibberson M, Franklin I, Binnert C, Pende M, Gjinovci A, Hansotia T, Drucker DJ, Wollheim C, Burcelin R, Thorens B.

J Clin Invest. 2004 Feb;113(4):635-45.

Supplemental Content

Support Center